Headaches are a common symptom of a stressful lifestyle, your body not feeling well and other issues. While headaches can be dealt with easily, migraines are not so easy to handle. Migraines are a type of headache that feels like severe throbbing and pulsing sensation, almost like you are hearing your own heartbeat in your brain, usually on one side of the brain. Many people believe that migraines are not that big of a deal because you just have to deal with the pain, but that is not all migraine is, some people find it very difficult to do their daily tasks as they experience dizzying spells, nausea and extreme sensitivity to light and sound! These attacks can last hours and make it difficult for people to go about their daily lives as well. While there are medications available for migraine patients, these medications need time to take effect, so you may be in a lot of pain, but there are not many quick reliefs you can have in place other than learning the symptoms of a migraine attack and taking medication before it happens. But a new approval by the FDA may change this!

The U.S. Food and Drug Administration (FDA) has approved Symbravo, a new medicine to treat acute migraine attacks in adults. This means adults can now use Symbravo to get relief from their migraine symptoms. The FDA's decision was based on the results of three big studies, called Phase 3 trials. These trials involved over 21,000 migraine attacks, so the FDA has a lot of information about how well Symbravo works and how safe it is. The FDA only approves medicines that have been shown to be both safe and effective through a thorough testing process.

Importance of New Treatment Option

"Migraine attacks can happen suddenly and really mess up people's lives. It's estimated that over 39 million people in the U.S. alone get migraines," said Herriot Tabuteau, M.D., CEO of Axsome Therapeutics told US News. This shows how common migraines are and how important it is to have good treatments. "Symbravo gives patients and doctors a new option that can quickly stop a migraine attack, keep it away, and let people get back to their normal activities, all with just one dose." Having a medicine that can give fast and long-lasting relief from migraine pain is a big deal for millions of people. This new treatment is a real step forward in how we treat migraines.

Symbravo Trial Results, How Was It Approved

The trials took place in 3 steps, the Momentum trial study focused on people whose migraines had moderate to severe pain. The results showed that a lot more people taking Symbravo felt pain-free two hours after taking the medicine compared to those who took a placebo which is a dummy pill. Even better, many people felt relief for up to 24 and even 48 hours after just one dose. This long-lasting relief is really important for people with migraines because it means they can get back to their normal lives without worrying about the pain coming back. The study also looked at how many people were free from their worst symptom, like sensitivity to light or sound, or nausea. Symbravo worked better than the placebo in this area too.

While the intercept trial looked at people who took Symbravo when their migraine pain was still mild. Even when the pain was just starting, Symbravo was effective. The results were similar to the MOMENTUM trial, with many people getting pain relief and relief from their worst symptoms. Treating migraines early is often better because it can stop the pain from getting really bad.

And lastly the Movement trial which was to see how safe the medication is when people take it regularly. This study followed 706 people who had at least two migraines a month. The most common side effects people experienced were sleepiness and dizziness. While these side effects are important to know about, the study showed that Symbravo is generally safe for people to use on a regular basis.

Prime Minister Narendra Modi today launched the nationwide Human Papillomavirus (HPV) vaccination campaign for girls aged 14 years from Rajasthan's Ajmer.

The initiative marks a decisive step towards eliminating cervical cancer through timely HPV vaccination. Cervical cancer remains the second most common cancer among women in India. Nearly 80,000 new cases and over 42,000 deaths are reported annually in the country.

"Today, I have had the opportunity to launch the HPV vaccine campaign from Ajmer. This campaign is an important step towards empowering women and daughters of this country,” PM Modi said.

“For us, this was a sensitive issue tied to the insult of our sisters and daughters, one that made them ill. That is why we resolved it at a crucial turning point in their mission,” he added.

The World Health Organization has also lauded India's mission to launch the HPV vaccine and prevent the risk of cervical cancer.

“We are leaving no stone unturned to ensure that the daughters of the country are healthy and prosperous. The objective of this initiative is the prevention of cervical cancer," the Prime Minister, earlier wrote in a post on social media platform X.

The HPV Vaccination Campaign

The nationwide program, based on expert recommendations of the National Technical Advisory Group on Immunization (NTAGI), will target girls aged 14 years.

At 14, the HPV vaccine offers maximum preventive benefit, well before potential exposure to the virus.

"By prioritizing prevention at the right age, the program is expected to provide lifelong protection and significantly reduce the future burden of cervical cancer in the country," the government said.

“The HPV vaccine works best at 9-14 years, before exposure, and when the immune response is strongest. Studies show effectiveness is highest in younger age groups and decreases with age,” Dr. Parmod Kumar, Associate Professor in Medical Oncology, AIIMS Jodhpur, shared on X.

Vaccination under the national program will be voluntary and free of cost.

The HPV vaccination will be conducted exclusively at designated government health facilities, including Ayushman Arogya Mandirs (Primary Health Centers), Community Health Centers, Sub-District and District Hospitals, and Government Medical Colleges.

Cervical Cancer Burden In South East Asia

Despite being preventable, cervical cancer continues to claim the life of a woman every two minutes globally, and the WHO South-East Asia Region bears nearly one-quarter of the global burden.

Dr. Catharina Boehme, Officer-in-Charge, WHO South-East Asia, stated that the introduction of HPV vaccination at a national scale in India "will have a far-reaching impact". It will accelerate progress not only for the country, but for the region and the world, she said.

“This landmark step, led at the highest level of government, reflects India’s strong commitment to protecting adolescent girls from cervical cancer," said Dr. Boehme.

With today’s milestone, nine of the 10 countries in the Region now include HPV vaccination in their national immunization programs.

The WHO global targets for 2030 include vaccinating 90 percent of girls by age 15, screening 70 percent of women by ages 35 and 45, and ensuring 90 percent of women with pre-cancer and invasive cancer receive appropriate treatment.

A team of doctors in Uttar Pradesh successfully performed a rare and highly complex neuro-interventional procedure on a two-and-a-half-year-old girl that enabled significant neurological recovery.

The child initially had severe indigestion and mild fever. However, it quickly escalated into repeated seizures, altered sensorium, and sudden loss of movement.

At ApolloMedics Super Speciality Hospital, Lucknow, the child was diagnosed with deep Cerebral Venous Sinus Thrombosis (CVST) with multiple brain infarcts -- a condition associated with high mortality risk and potentially devastating long-term neurological disability.

“Deep cerebral venous thrombosis in toddlers is exceptionally rare, and neuro-intervention in pediatric stroke is particularly challenging because of the small size of vessels and increased risk of bleeding,” said Dr. Dewansh Mishra, Interventional Neuro-Radiologist, at ApolloMedics.

“Literature on catheter-directed thrombolysis in such young patients is limited. In this case, the child was deteriorating quickly, and timely escalation to precision neuro-intervention was crucial to prevent irreversible brain injury and give her the best possible chance of recovery,” he added.

The Rare Brain Surgery

Dr. Mishra said that the child was also diagnosed with Antiphospholipid Antibody (APLA) syndrome, a clotting disorder that increases the tendency of blood to clot excessively.

Infection and dehydration further worsened the condition and accelerated stroke progression.

Recognizing the urgency, a multidisciplinary team of doctors took a critical, high-risk decision to escalate treatment without delay. They performed intracranial catheter-directed thrombolysis, under general anesthesia, preventing irreversible brain injury in the toddler.

Through the femoral vein in the thigh, a microcatheter was carefully navigated into the intracranial venous system, and clot-dissolving medication was delivered directly at the site of thrombosis to restore venous drainage. This was successful in limiting further neurological damage.

"After nearly three weeks of intensive care and rehabilitation, the child was discharged with significant neurological recovery. She is now able to walk, speak, and perform activities that children of her age do," the hospital said in a statement.

The case, marked by rapid deterioration and a narrow window for intervention, will be presented at the Indian National Stroke Conference 2026 in Kochi, underlining both its clinical significance and the growing capabilities of advanced stroke care in India.

Can Stroke Occur In Very Young Children?

While stroke is more common in adults than in children, the condition can occur in children and debilitate their lives.

Pediatric stroke is a rare condition affecting one in every 4,000 newborns and an additional 2,000 older children each year.

Stroke in young children is similar to that of adults and is caused by a brain injury due to the interruption of blood flow to part of the brain.

In young children, the diagnosis is often delayed. A stroke typically begins suddenly in children and infants, with Seizures the most common symptom.

Extreme sleepiness or altered mental status and a tendency to use only one side of the body are other major symptoms.

72 tigers have died due to an illness in Thailand's Chiang Mai. This happened is the span of less than two weeks this month. Facilities of Tiger Kingdom Chiang Mai, have been concerned, as this is a park where visitors can touch and interact with the big cats.

As per a BBC report, the local livestock department said that samples from tigers showed canine distemper virus. However, authorities have not yet confirmed how the outbreak happened. The samples were collected from tigers' bodies, the chicken they eat and their surroundings.

In a news conference, officials told that the virus was no longer spreading and that no more tigers were dying. The officials also stated that no humans had been infected.

The remains of the tigers have been buried and a recommendation was made for the gravely ill tigers to be euthanized, said the authorities. Somchuan Ratanamungklanon, director of the national livestock department, previously told local media, "By the time we realized they were sick, it was already too late." He noted that it was harder to detect the sickness in tigers compared to animals like common household cats or dogs.

Read: This Zoonotic Disease Of Himalayas Is Re-emerging But Recognition Remains Poor

Previously, the provincial livestock office had told that preliminary tests showed the tigers were infected with feline parvovirus. While some local officials also suspected that the outbreak was stemmed from contaminated raw chicken meat that was fed to tigers as per the Bangkok Post.

As per the Thai PBS report, none of the veterinarians or other staff working in the Chiang Mai tiger enclosures had fallen ill from canine distemper virus. However, the disease control department said that they have been placed under observation for 21 days.

Canine Distemper: The Virus That Killed 72 Tigers In Thailand

As per the American Veterinary Medical Association, canine distemper is a contagious and serious disease caused by the canine distemper virus. The virus attacks the respiratory, gastrointestinal, and nervous system of canines, including dogs, cats, and other wild canines, which includes foxes, wolves, tigers, big cats, raccoons, and skunks, etc.

The signs of canine distemper includes:

• Discharge from the eyes and nose
• Fever
• Coughing
• Lethargy
• Reduced appetite
• Vomiting
• Diarrhea

There are certain neurological signs too that can be noted:

• Walking in circles, unable to follow a straight path
• Head tilt
• Lack of coordination
• Muscle twitches
• Convulsions with jaw-chewing movements (“chewing gum fits”) and drooling
• Seizures
• Partial or complete paralysis

Is Canine Distemper Contagious to Humans?

As per PetMD, there is no evidence that humans can get canine distemper. Blue Cross UK also states that canine distemper virus is not infectious to humans and poses no known health threat to people. While it could be related to human measles virus, it does not cross over to cause illness in humans.

Read: Is There A Difference Between Zoonotic, Non-Zoonotic And Reverse Zoonotic Diseases

How Did The Tigers In Thailand Get Canine Distemper?

Many animal right groups are blaming the poor living conditions of captives as the reason for the virus. They say that tigers used for entertainment in Thailand lived in unclean enclosures. As per the Wildlife Friends Foundation Thailand, the tigers' deaths exposed the "extreme vulnerability of captive wildlife facilities to infectious disease". "Tragedies like this would be far less likely to happen" if tourists "stayed away" from these attractions, Peta Asia said in a statement.

Tiger Kingdom Chiang Mai has been temporarily closed for two weeks to carry out the disinfection work.